ESSA Pharma - EPIX Stock Forecast, Price & News

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Analysts Set New Price Targets

Separately, Piper Sandler reduced their price target on shares of ESSA Pharma from $50.00 to $20.00 in a report on Thursday, May 12th.

ESSA Pharma Stock Performance

EPIX Stock opened at $3.00 on Monday. The company's 50-day simple moving average is $3.64 and its 200 day simple moving average is $6.02. ESSA Pharma has a 52 week low of $2.41 and a 52 week high of $21.85.

ESSA Pharma (NASDAQ:EPIX - Get Rating) (TSE:EPI) last posted its quarterly earnings results on Tuesday, May 10th. The company reported ($0.25) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.25). As a group, analysts anticipate that ESSA Pharma will post -1.01 earnings per share for the current year.

Insiders Place Their Bets

In related news, major shareholder Growth N. V. Biotech acquired 300,000 shares of ESSA Pharma stock in a transaction dated Monday, July 18th. The stock was bought at an average price of $3.16 per share, with a total value of $948,000.00. Following the transaction, the insider now directly owns 5,879,583 shares in the company, valued at approximately $18,579,482.28. The purchase was disclosed in a filing with the SEC, which is accessible through this link. In other ESSA Pharma news, major shareholder Growth N. V. Biotech acquired 300,000 shares of the business's stock in a transaction dated Monday, July 18th. The stock was bought at an average price of $3.16 per share, with a total value of $948,000.00. Following the completion of the acquisition, the insider now owns 5,879,583 shares of the company's stock, valued at $18,579,482.28. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Growth N. V. Biotech acquired 347,204 shares of the stock in a transaction on Thursday, July 14th. The stock was bought at an average price of $2.79 per share, with a total value of $968,699.16. Following the transaction, the insider now directly owns 5,337,918 shares of the company's stock, valued at approximately $14,892,791.22. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 652,091 shares of company stock worth $1,931,165. 9.90% of the stock is currently owned by insiders.